Brief: Valeo Pharma Enters Into An Agreement For Ophthalmic Products, Prxiidra® And Prsimbrinza®, In Canada
02/08/2022 12:43
Aug 2 (Reuters) - Valeo Pharma Inc VPH.TO :
* VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC
PRODUCTS,
PRXIIDRA® AND PRSIMBRINZA®, IN CANADA
* VALEO PHARMA - TO START RECOGNIZING REVENUES FROM XIIDRA
AND
SIMBRINZA IN Q4-22
* VALEO PHARMA INC - AGREEMENT IS EFFECTIVE JULY 29, 2022
AND WILL
CONTINUE FOR AN INITIAL TERM OF SEVEN YEARS
Source text for Eikon: ID:nCNWWr2G9a
Further company coverage: VPH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valeo Pharma
See all newsBrief: Valeo Pharma Says Co Initiates Restructuring Proceedings
Brief: Valeo Pharma Amends Credit Facility With Sagard Healthcare Royalty Partners
Brief: Valeo Pharma Announces Restructuring Of Commercial Field Operations To Support Path To Profitability
Brief: Valeo Pharma Announces Appointment Of Mr. Al Moghaddam To Board Of Directors
Brief: Valeo Pharma Amends Agreement With Novartis Pharmaceuticals Canada